Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer
Emily K. Kleczko, Jeff Kwak, Erin L. Schenk, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 104

Showing 1-25 of 104 citing articles:

A deep learning model to predict RNA-Seq expression of tumours from whole slide images
Benoît Schmauch, Alberto Romagnoni, Elodie Pronier, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 370
NEAT1 as a competing endogenous RNA in tumorigenesis of various cancers: Role, mechanism and therapeutic potential
Kun Li, Tongyue Yao, Yu Zhang, et al.
International Journal of Biological Sciences (2021) Vol. 17, Iss. 13, pp. 3428-3440
Open Access | Times Cited: 66
Biosensors for the detection of lung cancer biomarkers: A review on biomarkers, transducing techniques and recent graphene-based implementations
Lih Poh Lin, Michelle T.T. Tan
Biosensors and Bioelectronics (2023) Vol. 237, pp. 115492-115492
Closed Access | Times Cited: 35
Complement System: An Immunotherapy Target in Colorectal Cancer
Iman M. Talaat, Noha Mousaad Elemam, Maha Saber-Ayad
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 35
The proteomic landscape of soft tissue sarcomas
Jessica Burns, Christopher P. Wilding, Lukáš Krásný, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 22
PVT1 lncRNA in lung cancer: A key player in tumorigenesis and therapeutic opportunities
Mohammed Ageeli Hakami, Ali Hazazi, Farhan R. Khan, et al.
Pathology - Research and Practice (2023) Vol. 253, pp. 155019-155019
Closed Access | Times Cited: 20
AuNPs/CNC Nanocomposite with A “Dual Dispersion” Effect for LDI‐TOF MS Analysis of Intact Proteins in NSCLC Serum Exosomes
Liang Shan, Yongxia Qiao, Lifang Ma, et al.
Advanced Science (2024) Vol. 11, Iss. 12
Open Access | Times Cited: 6
Metabolic impairment of non-small cell lung cancers by mitochondrial HSPD1 targeting
Beatrice Parma, Vignesh Ramesh, Paradesi Naidu Gollavilli, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 34
RNA modification writer expression profiles predict clinical outcomes and guide neoadjuvant immunotherapy in non-small cell lung cancer
Bolun Zhou, Fenglong Bie, Ruochuan Zang, et al.
EBioMedicine (2022) Vol. 84, pp. 104268-104268
Open Access | Times Cited: 28
Harnessing mitochondrial metabolism and drug resistance in non-small cell lung cancer and beyond by blocking heat-shock proteins
Beatrice Parma, Heiko Wurdak, Paolo Ceppi
Drug Resistance Updates (2022) Vol. 65, pp. 100888-100888
Open Access | Times Cited: 27
Evaluation of the Prognostic Value of STEAP1 in Lung Adenocarcinoma and Insights Into Its Potential Molecular Pathways via Bioinformatic Analysis
Qiang Guo, Xixian Ke, Zhou Liu, et al.
Frontiers in Genetics (2020) Vol. 11
Open Access | Times Cited: 34
KIF11 Serves as an Independent Prognostic Factor and Therapeutic Target for Patients With Lung Adenocarcinoma
Zhaodong Li, Bingxin Yu, Fangyuan Qi, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 31
LncRNASGMS1‐AS1 regulates lung adenocarcinoma cell proliferation, migration, invasion, and EMT progression via miR‐106a‐5p/MYLI9 axis
Ting Liu, Chunli Yang, Weizhen Wang, et al.
Thoracic Cancer (2021) Vol. 12, Iss. 14, pp. 2104-2112
Open Access | Times Cited: 29
Investigating the role of Kinesin family in lung adenocarcinoma via integrated bioinformatics approach
Gulnaz Tabassum, Prithvi Singh, Rishabh Gurung, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-PD1 therapy
Zhong-Chen Li, Jie Wang, He-Bin Liu, et al.
Cell Reports (2024) Vol. 43, Iss. 3, pp. 113877-113877
Open Access | Times Cited: 4
Are tumor-associated carbohydrates the missing link between the gut microbiome and response to immune checkpoint inhibitor treatment in cancer?
Zoltán Szállási, Aurél Prósz, Zsófia Sztupinszki, et al.
OncoImmunology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Increasing cisplatin exposure promotes small-cell lung cancer transformation after a shift from glucose metabolism to fatty acid metabolism
Qiuyu Zhao, Wenjun Liu, Jianguang Wang, et al.
Journal of Cancer Research and Clinical Oncology (2025) Vol. 151, Iss. 3
Open Access
The multiverse of CD46 and oncologic interactions
M. Kathryn Liszewski, John P. Atkinson
Journal of Clinical Investigation (2025) Vol. 135, Iss. 9
Open Access
The complement system and kidney cancer: pathogenesis to clinical applications
Ravikumar Aalinkeel, Richard J. Quigg, Jessy J. Alexander
Journal of Clinical Investigation (2025) Vol. 135, Iss. 9
Open Access
miR-139-5p Inhibits Lung Adenocarcinoma Cell Proliferation, Migration, and Invasion by Targeting MAD2L1
Jianfeng Li, Xi He, Xiaotang Wu, et al.
Computational and Mathematical Methods in Medicine (2020) Vol. 2020, pp. 1-10
Open Access | Times Cited: 31
(−)-Oleocanthal as a Dual c-MET-COX2 Inhibitor for the Control of Lung Cancer
Abu Bakar Siddique, Phillip Kilgore, Afsana Tajmim, et al.
Nutrients (2020) Vol. 12, Iss. 6, pp. 1749-1749
Open Access | Times Cited: 27
Inflammation, immunity, and vascular remodeling in pulmonary hypertension; Evidence for complement involvement?
Maria G. Frid, Joshua M. Thurman, Kirk C. Hansen, et al.
Global Cardiology Science and Practice (2020) Vol. 2020, Iss. 1
Open Access | Times Cited: 26
How Does Complement Affect Hematological Malignancies: From Basic Mechanisms to Clinical Application
Shanshan Luo, Moran Wang, Huafang Wang, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 25
Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value
Xupeng Chai, Eloy Yinwang, Zenan Wang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 23
Elevated circASCC3 limits antitumor immunity by sponging miR-432–5p to upregulate C5a in non-small cell lung cancer
Jian Gao, Ling-Xian Zhang, Yong-Qiang Ao, et al.
Cancer Letters (2022) Vol. 543, pp. 215774-215774
Closed Access | Times Cited: 15
Page 1 - Next Page

Scroll to top